Dynavax Technologies (NASDAQ:DVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Dynavax Technologies (NASDAQ:DVAX) had its target price increased by analysts at HC Wainwright from $29.00 to $31.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 148.40% from the stock’s previous close.

Dynavax Technologies Trading Down 1.2 %

Shares of DVAX stock opened at $12.48 on Tuesday. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.41. The company has a 50 day moving average price of $12.75 and a 200 day moving average price of $11.64. The stock has a market capitalization of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Institutional Trading of Dynavax Technologies

Several hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. purchased a new stake in Dynavax Technologies during the 3rd quarter worth about $8,291,000. Entropy Technologies LP acquired a new position in shares of Dynavax Technologies during the third quarter worth about $462,000. Bank of Montreal Can increased its stake in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after buying an additional 82,449 shares during the period. Millennium Management LLC purchased a new position in Dynavax Technologies in the second quarter worth approximately $17,615,000. Finally, Nordea Investment Management AB grew its holdings in Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after acquiring an additional 232,690 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.